| 查看: 6213 | 回复: 32 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
埃索美拉唑钠 药典标准
|
|||
|
埃索美拉唑钠 有没有药典标准呀 一直没找到... 没有的话，自己生产的话这标准是参考 埃索美拉唑镁 还是 奥美拉唑钠 |
回复此楼» 本帖已获得的红花（最新10朵）
CZX99» 猜你喜欢
新版scifinder
已经有1人回复
-
安捷伦液相色谱柱与方法开发指南
已经有4人回复
-
药理学论文润色/翻译怎么收费?
已经有68人回复
-
2026申博
已经有0人回复
-
合成
已经有0人回复
-
氨基酸的酰化反应，求大佬解答
已经有0人回复
-
26考博申请 学or专
已经有15人回复
-
26年申博——已发SCI6篇
已经有13人回复
-
碱缸的配制
已经有5人回复
-
新！澳门科技大学诚招2026年秋季药剂学/生物材料方向博士研究生（申请-考核制）
已经有16人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 埃索美拉唑钠原料的开发
已经有16人回复
- 埃索美拉唑钠的重结晶方法
已经有18人回复
- 求助埃索美拉唑钠的研发背景资料
已经有8人回复
- 埃索美拉唑镁肠溶微丸释放时变色
已经有13人回复
- 大家有没有做埃索美拉唑钠项目的进来交流一下！
已经有47人回复
- 【求助】高手请进 关于埃索美拉唑钠盐的紫外图谱
已经有8人回复
- 【求助】埃索美拉唑钠
已经有17人回复
» 抢金币啦！回帖就可以得到:
-
新加坡国立大学张阳教授课题组招聘博士后（AI与生物医学方向）
+1/181
-
湖南师范大学蒋乐勇教授课题组招收2026届“申请-考核”制博士生
+1/177
-
Analytical Science Advances（Wiley出版社）长期征稿中...
+1/96
-
接样SEM/XPS/XRD/FTIR/BET等多种测试/提供预存服务
+1/86
-
诚聘生物有化学方向博士后
+1/77
-
重庆大学杰青团队诚招2026年博士研究生
+2/64
-
南京-栖霞区-尧化门附件有房子出租吗？
+1/31
-
国家青年人才叶立群教授课题组招收2026级博士研究生
+1/30
-
哈工大深圳校区 博士招生 燃料电池/电解制氢
+1/29
-
人到中年，还能干啥
+1/22
-
山东大学集成电路学院招收2026年9月入学的博士研究生
+1/16
-
肿瘤免疫课题组招聘 博后
+1/14
-
中南大学化学化工学院高性能聚合物团队2026年诚聘博士后或青年教师
+1/8
-
河南师范大学植物生殖生物学科研团队博士招聘
+1/8
-
澳门大学 应用物理及材料工程研究院 孙国星课题组招收博士（2026/2027学年）
+1/6
-
SCI计算机相关论文
+1/5
-
如何确定博后期间的研究方向？
+1/4
-
广西大学化学化工学院江俊教授课题组招收2026年博士研究生
+1/3
-
长春工业大学 机电工程学院 韩玲教授 招收审核制2026年秋季入学博士生
+1/1
-
电子科技大学能源材料界面课题组2026年博士生招生
+1/1
25楼2012-01-20 21:28:30
2楼2011-08-30 14:35:50
★
hao8431(金币+1):谢谢参与
hao8431(金币+1):谢谢参与
|
以下是USP34版友原料药镁盐的标准 Esomeprazole Magnesium (es'' oh mep' ra zole mag nee' zee um). C34H36MgN6O6S2·3H2O Trihydrate: 767.17 C34H36MgN6O6S2 Anhydrous: 713.12 1H-Benzimidazole,5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl], magnesium salt (2:1), trihydrate; 5-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole, magnesium salt (2:1), trihydrate [217087-09-7]. DEFINITION Esomeprazole Magnesium contains NLT 98.0% and NMT 102.0% of C34H36MgN6O6S2, calculated on the anhydrous basis. IDENTIFICATION • A. INFRARED ABSORPTION 197K • B. The Sample solution, prepared and tested as directed in the test for Content of Magnesium, exhibits a significant absorption at 285.2 nm. ASSAY • PROCEDURE Solution A: Dissolve 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Solution B: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 100 mL. Mobile phase: Acetonitrile and Solution A (7:13) Standard solution: Transfer 10 mg of USP Omeprazole RS to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of omeprazole. ] Sample solution: Transfer 10 mg of Esomeprazole Magnesium to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of esomeprazole magnesium. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 1 mL/min Injection size: 20 μL System suitability Sample: Standard solution Suitability requirements Column efficiency: NLT 2000 theoretical plates Relative standard deviation: NMT 2.0% Analysis Samples: Standard solution and Sample solution Calculate the percentage of C34H36MgN6O6S2 in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × (CS/CU) × [Mr1/(2 × Mr2)] × 100 Acceptance criteria: 98.0%–102.0% on the anhydrous basis OTHER COMPONENTS • CONTENT OF MAGNESIUM Lanthanum solution: Transfer 58.7 g of lanthanum oxide into a 1000-mL volumetric flask, wet the substance with some water, and dissolve by cautious addition of 250 mL of hydrochloric acid in 20- to 30-mL portions, cooling between the additions. Add water while stirring, cool to room temperature, and dilute with water to volume. [NOTE—Store the solution in a plastic bottle. ] Standard stock solution: 1000 μg/mL of magnesium in water, from a commercially prepared atomic absorption standard solution. [NOTE—Store the solution in a plastic bottle. ] Standard solution A: Transfer 10.0 mL of Standard stock solution to a 500-mL volumetric flask, add 50 mL of 1 N hydrochloric acid, and dilute with water to volume. Transfer 20.0 rU = = peak response from the Sample solution rS = = peak response from the Standard solution CS = = concentration of omeprazole in the Standard solution (mg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (mg/mL) Mr1 = = molecular weight of esomeprazole magnesium, 713.12 Mr2 = = molecular weight of omeprazole, 345.42 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. [NOTE— This solution contains 2 μg/mL of magnesium. ] Standard solution B: Combine 5.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.1 μg/mL). Standard solution C: Combine 10.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.2 μg/mL). Standard solution D: Combine 15.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.3 μg/mL). Standard solution E: Combine 20.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.4 μg/mL). Standard solution F: Combine 25.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.5 μg/mL). [NOTE—Concentrations of the Standard solutions and the Sample solution may be modified to fit the linear or working range of the instrument. When using instruments with a linear calibration graph, the number of Standard solutions can be reduced. ] Blank solution: Transfer 4.0 mL of Lanthanum solution to a 100-mL volumetric flask, and dilute with water to volume. Sample solution: Transfer 250 mg of Esomeprazole Magnesium to a 100-mL volumetric flask, add 20 mL of 1 N hydrochloric acid, swirl until dissolved, and dilute with water to volume. Allow to stand for 30 min. Transfer 10.0 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. Transfer 10.0 mL of the solution to another 100-mL volumetric flask, add 4.0 mL of Lanthanum solution, and dilute with water to volume. Spectrometric conditions (See Spectrophotometry and Light-Scattering 851 .) Mode: Atomic absorption spectrophotometer Flame: Air–acetylene Analytical wavelength: 285.2 nm Analysis Samples: Standard solution B, Standard solution C, Standard solution D, Standard solution E, Standard solution F, Blank solution, and Sample solution Determine the concentration, Cs, in μg/mL, of magnesium in the Sample solution using the calibration graph. Calculate the percentage of magnesium in the portion of Esomeprazole Magnesium taken: Result = (CS/CU) × (100/(100 F)) × 100 CS = = content of magnesium in the Sample solution as calculated above (μg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (μg/mL) F = = content of water in Esomeprazole Acceptance criteria: 3.30%–3.55%, on anhydrous basis IMPURITIES Organic Impurities • PROCEDURE 1 Solution A: 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Mobile phase: Acetonitrile and Solution A (11:29). [NOTE—To improve the resolution, the composition may be changed to 1:3, if necessary. ] System suitability solution: 1 mg of USP Omeprazole RS and 1 mg of USP Omeprazole Related Compound A RS in 25 mL of Mobile phase. [NOTE—Omeprazole Related Compound A is omeprazole sulfone. ] Sample solution: 4 mg of Esomeprazole Magnesium in 25 mL of Mobile phase. [NOTE— Prepare this solution fresh. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 0.8–1 mL/min Injection size: 50 μL System suitability Sample: System suitability solution [NOTE—For relative retention times, see Impurity Table 1. ] Suitability requirements Resolution: NLT 3 between omeprazole related compound A and omeprazole Analysis Sample: Sample solution Record the chromatogram for at least 4.5 times the retention time of the omeprazole peak, and measure the peak responses. Identify the impurities based on the retention times shown in Impurity Table 1. Calculate the percentage of any individual impurity in the portion of Esomeprazole Magnesium taken: Result = (rU/rT) × 100 Magnesium, as determined in Specific Tests, Water Determination (%) rU = = peak response for each impurity = = sum of all peak responses Acceptance criteria Individual impurities: See Impurity Table 1. Total impurities: NMT 0.5% Impurity Table 1 • PROCEDURE 2: ENANTIOMERIC PURITY Solution A: Mix 70 mL of 1 M monobasic sodium phosphate with 20 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. Diluent: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Mobile phase: Acetonitrile and Solution A (3:17) System suitability solution: 2 mg of USP Omeprazole RS in 10 mL of Diluent. Dilute 1.0 mL of this solution with Diluent to 50 mL. Sample solution: 40 mg of Esomeprazole Magnesium in 5 mL of methanol, and dilute with Diluent to 25 mL. Dilute 1 mL of this solution with Diluent to 50 mL. Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 302 nm Column: 4.0-mm × 10-cm; packing L41 Flow rate: 0.6 mL/min Injection size: 20 μL System suitability Sample: System suitability solution Suitability requirements Resolution: NLT 3 between the enantiomer peaks. [NOTE—The elution order is the Renantiomer, followed by the esomeprazole peak, which is the S-enantiomer. ] Analysis rT Name Relative Retention Time Acceptance Criteria, NMT (%) Omeprazole N-oxide a 0.45 0.1 Omeprazole sulfoneb (related compound A) 0.8 0.2 Any other individual impurities — 0.1 Omeprazole 1.0 — a 4-Methoxy-2-[[(RS)-(5-methoxy-1H-benzimidazol-2-yl)sulfinyl]methyl]-3,5- dimethylpyridine 1-oxide. b 5-Methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1Hbenzimidazole. Sample: Sample solution Calculate the percentage of the R-enantiomer in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × 100 Acceptance criteria: NMT 0.2% of the R-enantiomer SPECIFIC TESTS • WATER DETERMINATION, Method I 921 : 6.0%–8.0% • COLOR OF SOLUTION Sample solution: 20 mg/mL of Esomeprazole Magnesium in methanol Analysis: Determine the absorbance of this solution at 440 nm, in 1-cm cells, using methanol as the blank. Acceptance criteria: NMT 0.2 ADDITIONAL REQUIREMENTS • PACKAGING AND STORAGE: Preserve in tight containers, protected from light. Store at room temperature. • USP REFERENCE STANDARDS 11 USP Esomeprazole Magnesium RS USP OMEPRAZOLE RS USP OMEPRAZOLE RELATED COMPOUND A RS Omeprazole sulfone, 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]- 1H-benzimidazole. C17H19N3O4S 361.42 [CAS-88546-55-8]. Auxiliary Information— Please check for your question in the FAQs before contacting USP. USP34–NF29 Page 2741 Pharmacopeial Forum: Volume No. 35(3) Page 550 Chromatographic Column— ESOMEPRAZOLE MAGNESIUM rU = = peak response for the R-enantiomer rS = = sum of the peak responses for esomeprazole and R-enantiomer Topic/Question Contact Expert Committee Monograph Elena Gonikberg, Ph.D. Principal Scientific Liaison 1-301-816-8251 (SM32010) Monographs - Small Molecules 3 Reference Standards RS Technical Services 1-301-816-8129 rstech@usp.org Chromatographic columns text is not derived from, and not part of, USP 34 or NF 29 还有EP7.0里面是三水合物的标准，如果需要可以联系我，或留下邮箱我把标准发给你！ |
3楼2011-08-30 14:44:06
4楼2011-08-30 14:50:28